The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

Scientists from the Children's Hospital of Philadelphia (CHOP) say they have found how mutations in a protein network drive several high-risk leukemias, particularly chronic myelomonocytic leukemia ...

Stage 1 myelofibrosis is a chronic condition with minimal symptoms, requiring early diagnosis for effective monitoring and intervention. Treatment options include active surveillance, JAK inhibitors, ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...

Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...